1700633699
在临床上为了达到最佳的肾脏保护作用需要有清楚的治疗目标以及持续不断的努力。基于可以获得的研究基础上我们提出了7点治疗目标（见表6-1）。RAS阻断应作为基本首选的肾保护药物，如单用不能达到血压以及蛋白尿的控制目标，应考虑联合用药，使血压控制在130/80mm Hg以下，应经常定期监测蛋白尿水平，应给予充分治疗，控制最低程度的蛋白尿，虽然没有前瞻性研究确定合适的蛋白尿控制水平，但目前认为蛋白尿控制＜0.5g/d是比较合适的。在临床实践中还应该积极避免可能恶化肾功能的各种因素。目前正在进行的各种研究有助于进一步明确CRF的复杂发病机制。这对进一步寻找延缓CKD进展提高理论基础。
1700633700
1700633701
表6-1 干预措施以及治疗目标
1700633702
1700633703
1700633704
1700633705
1700633706
【思考题】
1700633707
1700633708
1．试述慢性肾衰进展的机制。
1700633709
1700633710
2．慢性肾衰进展的治疗策略有哪些？
1700633711
1700633712
参考文献
1700633713
1700633714
[1] National Kidney Foundation-K/DOQI. Clinical practice guidelines for chronic kidney disease, evaluation, classification, and stratification. Am J Kidney Dis, 2002, 39(suppl 1):S1-S266.
1700633715
1700633716
[2] Iseki K, Ikemiya Y, Iseki C, Takishita S Proteinuria and the risk of developing end-stage renal disease. Kidney Int, 2003, 63:1468-1474.
1700633717
1700633718
[3] Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens, 2004, 13:31-7.
1700633719
1700633720
[4] Kidney Disorder Outcomes Quality Initiative（K/DOQI）(2004）K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis, 2004, 43:S1-S290.
1700633721
1700633722
[5] Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual protein-uria. Kidney Int, 2003, 63:2254-61.
1700633723
1700633724
[6] Ruggenenti P, Fassi A, Ilieva AP, Nephrologic diabetes complications trial（BENEDICT）investigators preventing microalbuminuria in type 2 diabetes. N Engl J Med, 2004, 351:1941-1951.
1700633725
1700633726
[7] Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA Management of glomerular proteinuria: a commentary. J Am Soc Nephrol, 2003, 14:3217-3232
1700633727
1700633728
[8] Wright JT Jr, Bakris G, Greene T. African American study of kidney disease and hypertension: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2003, 288:2421-2431.
1700633729
1700633730
[9] Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-Ⅱ receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease（COOPERATE): a randomised controlled trial. Lancet, 2003, 361:117-124.
1700633731
1700633732
[10] Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol, 2005, 16:3038-3045.
1700633733
1700633734
[11] Brenner BM. Retarding the progression of renal disease. Kidney Int, 2003, 64:370-8.
1700633735
1700633736
[12] Levey AS, Greene T, Sarnak MJ, Effect of dietary protein restriction on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease（MDRD）Study. Am J Kidney Dis, 2006, 48:876-888.
1700633737
1700633738
[13] Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol, 2007, 117:64-74.
1700633739
1700633740
[14] Eto N, Wada T, Inagi R et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int, 2007, 72:455-463.
1700633741
1700633742
[15] Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis, 2000, 35:687-94.
1700633743
1700633744
（陈江华 田炯）
1700633745
1700633746
1700633747
1700633748